Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2001 3
2002 3
2003 11
2004 13
2005 33
2006 47
2007 44
2008 37
2009 26
2010 28
2011 19
2012 18
2013 16
2014 19
2015 20
2016 18
2017 19
2018 11
2019 10
2020 40
2021 43
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

443 results
Results by year
Filters applied: . Clear all
Page 1
Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
Zhang XY, Huang HJ, Zhuang DL, Nasser MI, Yang MH, Zhu P, Zhao MY. Zhang XY, et al. Infect Dis Poverty. 2020 Jul 20;9(1):99. doi: 10.1186/s40249-020-00691-6. Infect Dis Poverty. 2020. PMID: 32690096 Free PMC article. Review.
We discovered through the autodock simulations that Met124 plays a key role in the efficiency of drugs targeting ACE2, such as remdesivir, chloroquine, ciclesonide and niclosamide, and may be a potential target in COVID-19....
We discovered through the autodock simulations that Met124 plays a key role in the efficiency of drugs targeting ACE2, such as remdesivir, c …
Ciclesonide.
[No authors listed] [No authors listed] 2018 Oct 31. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. 2018 Oct 31. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. PMID: 30000518 Free Books & Documents. Review.
Local and systemic safety of intranasal corticosteroids.
Sastre J, Mosges R. Sastre J, et al. J Investig Allergol Clin Immunol. 2012;22(1):1-12. J Investig Allergol Clin Immunol. 2012. PMID: 22448448 Free article. Review.
A review of the published literature indicates that the side effect profiles of INCs consist primarily of a low incidence of mostly mild and often transient local AEs, such as nasal irritation and epistaxis.The second-generation INC agents currently in use (mometasone furoate nas …
A review of the published literature indicates that the side effect profiles of INCs consist primarily of a low incidence of mostly mild and …
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.
Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, Shimojima M, Fukushi S. Matsuyama S, et al. J Virol. 2020 Dec 9;95(1):e01648-20. doi: 10.1128/JVI.01648-20. Print 2020 Dec 9. J Virol. 2020. PMID: 33055254 Free PMC article.
Of note, ciclesonide suppressed the replication of all these mutants by 90% or more, suggesting that these mutants cannot completely overcome ciclesonide blockade. ...Ciclesonide is safe; indeed, it can be administered to infants at high concentrations. ...
Of note, ciclesonide suppressed the replication of all these mutants by 90% or more, suggesting that these mutants cannot completely …
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S. Jeon S, et al. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00819-20. doi: 10.1128/AAC.00819-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32366720 Free PMC article.
Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects....
Some drug candidates showed very low 50% inhibitory concentrations (IC(50)s), and in particular, two FDA-approved drugs-niclosamide and c
Different types of intranasal steroids for chronic rhinosinusitis.
Chong LY, Head K, Hopkins C, Philpott C, Burton MJ, Schilder AG. Chong LY, et al. Cochrane Database Syst Rev. 2016 Apr 26;4:CD011993. doi: 10.1002/14651858.CD011993.pub2. Cochrane Database Syst Rev. 2016. PMID: 27115215 Free article. Review.
SELECTION CRITERIA: Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing first-generation intranasal corticosteroids (e.g. beclomethasone dipropionate, triamcinolone acetonide, flunisolide, budesonide) with second-generation intranasal co …
SELECTION CRITERIA: Randomised controlled trials (RCTs) with a follow-up period of at least three months comparing first-generation intranas …
Ciclesonide.
Reynolds NA, Scott LJ. Reynolds NA, et al. Drugs. 2004;64(5):511-9; discussion 520-1. doi: 10.2165/00003495-200464050-00005. Drugs. 2004. PMID: 14977388 Clinical Trial.
Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of adrenal function in 52-week studies. The long-term (>52 weeks) systemic effects of ciclesonide remain unknown....
Inhaled ciclesonide was generally well tolerated in patients with asthma. Ciclesonide did not suppress biochemical markers of …
Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthma.
Yeo SH, Aggarwal B, Shantakumar S, Mulgirigama A, Daley-Yates P. Yeo SH, et al. Expert Rev Respir Med. 2017 Oct;11(10):763-778. doi: 10.1080/17476348.2017.1361824. Epub 2017 Aug 4. Expert Rev Respir Med. 2017. PMID: 28752776 Review.
Areas covered: This systematic review evaluated randomized controlled trials (RCTs) that compared the efficacy and safety of inhaled fluticasone propionate (FP) with other ICS including beclomethasone dipropionate (BDP), budesonide (BUD) and ciclesonide (CIC). PubMed was s …
Areas covered: This systematic review evaluated randomized controlled trials (RCTs) that compared the efficacy and safety of inhaled flutica …
Systemic side effects of inhaled corticosteroids in patients with asthma.
Dahl R. Dahl R. Respir Med. 2006 Aug;100(8):1307-17. doi: 10.1016/j.rmed.2005.11.020. Epub 2006 Jan 18. Respir Med. 2006. PMID: 16412623 Free article. Review.
Therefore, cortisol may be a relevant surrogate marker to identify the potential for adverse effects from ICS therapy. Ciclesonide is a new generation ICS with demonstrable safety and efficacy in the treatment of asthma. The unique pharmacologic characteristics of cicle
Therefore, cortisol may be a relevant surrogate marker to identify the potential for adverse effects from ICS therapy. Ciclesonide is …
443 results